HMOX1 has also been reported as upregulated in two hereditary blood diseases, sickle cell disease and beta-Thalassemia, where NRF2 activation can potentially alleviate disease severity by reducing oxidative damage, inhibiting haemoglobin S polymerization, and promoting foetal haemoglobin expression [89]. Here, NFE2L2 is linked to sickle cell disease.